|
注册号: Registration number: |
ChiCTR2300068786 |
|
最近更新日期: Date of Last Refreshed on: |
2023-07-31 09:43:41 |
|
注册时间: Date of Registration: |
2023-02-28 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
虚拟现实运动与真实运动对超重和肥胖青少年的干预作用研究 |
|
Public title: |
Intervention study of virtual reality-based exercise and exercise in overweight and obese adolescents |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
虚拟现实运动与真实运动对超重和肥胖青少年的干预作用研究 |
|
Scientific title: |
Intervention study of virtual reality-based exercise and exercise in overweight and obese adolescents |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李华婷 |
研究负责人: |
李华婷 |
|
Applicant: |
Li Huating |
Study leader: |
Li Huating |
|
申请注册联系人电话: Applicant telephone: |
+86 139 1650 2465 |
研究负责人电话:
Study leader's |
+86 139 1650 2465 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
huarting99@sjtu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
huarting99@sjtu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市徐汇区宜山路600号 |
研究负责人通讯地址: |
上海市徐汇区宜山路600号 |
|
Applicant address: |
600 Yishan Road, Xuhui District, Shanghai |
Study leader's address: |
600 Yishan Road, Xuhui District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海交通大学医学院附属第六人民医院 |
||
|
Applicant's institution: |
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine |
||
|
研究负责人所在单位: |
上海交通大学医学院附属第六人民医院 |
||
|
Affiliation of the Leader: |
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2022-104 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海市第六人民医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the Shanghai Sixth People’s Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-10-13 00:00:00 | ||
|
伦理委员会联系人: |
孙秀秀 |
||
|
Contact Name of the ethic committee: |
Xiuxiu Sun |
||
|
伦理委员会联系地址: |
上海市徐汇区宜山路600号 |
||
|
Contact Address of the ethic committee: |
600 Yishan Road, Xuhui District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
上海交通大学医学院附属第六人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市徐汇区宜山路600号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
600 Yishan Road, Xuhui District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
上海市重中之重临床医学中心和重点学科建设项目(2017ZZ01013);上海市临床重点专科建设项目(LY01.05.02) |
||||||||||||||||||||||
|
Source(s) of funding: |
Shanghai Municipal Key Clinical Specialty(2017ZZ01013); Shanghai Key Clinical Specialty Construction Project (LY01.05.02) |
||||||||||||||||||||||
|
研究疾病: |
超重与肥胖 |
||||||||||||||||||||||
|
Target disease: |
overweight and obesity |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本项研究主要探讨在饮食控制的基础上,VR运动与现实运动干预是否对超重和肥胖青少年的体脂含量具有改善作用,对体成分、糖脂代谢、认知功能、体适能等的影响,并通过系统生物学分析探索VR运动与真实运动对以上潜在表型改变的差异和机制。 |
||||||||||||||||||||||
|
Objectives of Study: |
The main purpose of this study is to explore whether VR exercise and real-world exercise intervention can improve body fat mass of overweight and obese adolescents based on diet administration, and the effects of VR exercise and real-world exercise on body composition, glycolipid metabolism, cognitive function and physical fitness. Furthermore, the differences and mechanisms between VR exercise and real-world exercise on the above potential phenotypic changes will be explored through systems biology analysis. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
训练包括热身、技能训练、小型比赛和放松练习等环节,VR足球、乒乓球训练的运动时间与频率与真实运动保持一致。每周训练3次,每次40分钟,共训练8周。其中8周共分4个周期(2周为一个周期)。根据逐渐递增运动负荷的训练学原则,四个周期的训练差别主要体现在运动负荷和训练强度方面。运动强度评定标准为%最大心率(HRmax),运动强度范围为60%-70%HRmax。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
Training includes a warm-up, skill training, small games and relaxation exercises, and the movement time and frequency of VR soccer and table tennis training are consistent with real sports. The training was performed three times a week for 40 minutes for a total of 8 weeks. 8 weeks were divided into 4 cycles (2 weeks as a cycle). According to the training principle of gradually increasing exercise load, the training difference of four cycles is mainly reflected in exercise load and training intensity. Exercise intensity is measured as %maximum heart rate (HRmax) and exercise intensity range from 60% to 70% HRmax. |
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.在筛选期前90天内参加有组织的减肥计划; 2.目前服用以下任何药物治疗:普拉姆林肽、奥利司他、唑尼沙胺、托吡酯、氯卡色林、芬特明、安非他酮、纳曲酮、胰高血糖素样肽-1(GLP-1)受体激动剂或二甲双胍(用于治疗肥胖症); 3.既往接受过肥胖外科治疗; 4.肌肉、骨骼或神经等组织器官损伤(妨碍运动训练); 5.非单纯性肥胖,包括内分泌与代谢性疾病(如库欣综合征、甲状腺功能低下、性腺功能减退、多囊卵巢综合征等)、肿瘤及创伤等; 6.严重精神疾病(如精神分裂症、双相情感障碍、重度抑郁)病史; 7.确认患有神经性贪食症障碍的受试者; 8.使用VR眩晕,存在障碍者; 9.研究者认为可能危及受试者安全或不遵守方案的任何情况。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Participate in an organized weight loss plan within 90 days prior to the screening period; 2. Currently taking any of the following drugs for treatment: pramlin peptide, Orlistat, Zonisamide, topiramate, clocasserin, phentermine, Bupropion, naltrexone, Glucagon-like peptide-1 receptor agonist or Metformin (for the treatment of obesity); 3. Previously received surgical treatment for obesity; 4. Damage to tissues and organs such as muscles, bones, or nerves (hindering exercise training); 5. Non simple obesity, including endocrine and metabolic diseases (such as Cushing's syndrome, hypothyroidism, hypogonadism, polycystic ovary syndrome, etc.), tumors, and trauma; 6. History of severe mental illness (such as schizophrenia, bipolar disorder, severe depression); 7. Confirming subjects with bulimia nervosa disorder; 8. Those who experience dizziness and obstacles when using VR; 9. Any situation that the researcher believes may endanger the safety of the subject or non-compliance with the protocol. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-03-01 00:00:00至 To 2024-03-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-03-01 00:00:00 至 To 2023-05-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
受试者将按1:1:1:1:1的比例随机分配进入对照组、真实足球训练组、真实乒乓球训练组、VR足球训练组、VR乒乓球训练组。随机序列将由一位独立的统计人员产生。随机序列对受试者和招募研究人员保密。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Participants will be randomized 1:1:1:1:1 into the control group, real-world soccer group, real-world table tennis group, VR soccer group and VR table tennis group. Randomization sequences will be prepared by an independent statistician. The random sequence is blind to participants and recruitment staff. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
受试者及实施运动干预的研究者知晓实验分组及干预手段,因研究的特殊性无法保持盲态;受试者入组及随访评估将由不知晓受试者分组 情况的第三方进行。 |
|
Blinding: |
Subjects and investigators who provide exercise interventions are aware of group assignments and interventions and are unable to remain blind due to the design of the study. Therefore, subject enrollment and follow-up assessments will be performed by third parties who are unaware of the group assignment and interventions. |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
试验完成后公开于http://www.chictr.org.cn |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After the trial is completed, it is available at http://www.chictr.org.cn |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
所有参与者的CRF由研究人员填写。在研究过程中CRF用于收集信息。原始文件将完好无损地保存在固定的地方,并上锁。根据中国的GCP原则,文件至少保存5年。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
All CRF for each participant should be filled out by study staff. The CRF is used to collect information during the study. Original files will be kept intact, stored in a fixed place, and locked. According to Chinese GCP principles, files should be kept for at least 5 years. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |